Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,358 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

NCT04338711
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified release (MR)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

NCT01874561
View directory record Official record
Conditions
Cardiac Conduction and Repolarization
Interventions
Custirsen, Placebo, Moxifloxacin
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 28, 2026, 10:07 AM EDT
Recruiting Not applicable Interventional

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors

NCT06938555
View directory record Official record
Conditions
Breast Cancer Survivor, Cancer Related Cognitive Difficulties, Sleep, Quality of Life
Interventions
Prolonged Nightly Fasting, Health Education Videos
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

TAK-329 Glucose Clamp Study

NCT01311076
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
TAK-329, Insulin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 28, 2026, 10:07 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

NCT05358756
View directory record Official record
Conditions
Healthy Subject
Interventions
SACT-1, EDURANT 25Mg Tablet
Drug
Lead sponsor
Aptorum International Limited
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

NCT00865059
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 28, 2026, 10:07 AM EDT
Recruiting Not applicable Interventional

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

NCT06826924
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Fasting, Ketone Supplementation
Behavioral · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

NCT03097016
View directory record Official record
Conditions
Renal Insufficiency
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

NCT00886093
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 28, 2026, 10:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

NCT05690932
View directory record Official record
Conditions
Formulation Bridging, Food Effect
Interventions
PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

NCT01702493
View directory record Official record
Conditions
Psoriasis
Interventions
Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 28, 2026, 10:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

NCT07607158
View directory record Official record
Conditions
Microbiome Analysis, Metabolomics
Interventions
Freeze-dried blueberry powder beverage
Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

NCT02525484
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pirfenidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 10:07 AM EDT
Terminated Phase 2 Interventional Results available

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

NCT01453088
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

NCT00911274
View directory record Official record
Conditions
Healthy
Interventions
Mycophenolate Mofetil, CellCept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

NCT01002378
View directory record Official record
Conditions
Dietary Fats, Pharmacokinetics
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 28, 2026, 10:07 AM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

NCT00649740
View directory record Official record
Conditions
Healthy
Interventions
Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsule 25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Ritonavir

NCT00983515
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ritonavir
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 28, 2026, 10:07 AM EDT